Track Pfizer Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.
1 Week returns: -5.49 %
Low
3,589.0
High
3,840.6
1 Month returns: -10.31 %
Low
3,589.0
High
4,123.9
1 Year returns: -31.90 %
Low
3,589.0
High
5,357.0
3 Year CAGR: -2.63 %
Low
3,589.0
High
6,451.1
5 Year CAGR: -6.97 %
Low
3,408.0
High
6,451.1
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.
Multi-year trends for Pfizer Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.
Pfizer Ltd. Shareholding Pattern
Quarterly breakdown of Pfizer Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.
Bulk, Block and Insider Trades
Recent bulk deals, block deals, and insider trading activity in Pfizer Ltd. shares as reported to NSE and BSE.
Frequently Asked Questions
What is the current share price of Pfizer Ltd.?
The current share price of Pfizer Ltd. is ₹ 3,610.35 as of 23 Oct 2026.
What is the market capitalisation of Pfizer Ltd.?
The market capitalisation of Pfizer Ltd. stands at ₹ 16,516.60 Cr.
What is the PE ratio of Pfizer Ltd.?
The Price-to-Earnings (PE) ratio of Pfizer Ltd. is 22.47 as of the latest trailing twelve months data.
What is the ROE and ROCE of Pfizer Ltd.?
Pfizer Ltd. has a Return on Equity (ROE) of 17.16% and a Return on Capital Employed (ROCE) of 19.70% as per the latest financial reports.
What is the 52-week high and low of Pfizer Ltd.?
The 52-week high of Pfizer Ltd. is - and the 52-week low is -.
What is the dividend yield of Pfizer Ltd.?
The dividend yield of Pfizer Ltd. is 2.08% based on the current market price.
What is the FII and DII holding in Pfizer Ltd.?
Foreign Institutional Investors (FII) hold 1.63%, Domestic Institutional Investors (DII) hold 17.50% and retail/public investors hold 14.04% of Pfizer Ltd. shares.
What sector does Pfizer Ltd. belong to?
Pfizer Ltd. operates in the Healthcare sector. 60% of analysts have a Buy or Strong Buy rating on Pfizer Ltd. with a consensus target price of ₹ 5,815.00, implying 61.06% upside from current levels.
What is the beta of Pfizer Ltd.?
The beta of Pfizer Ltd. is 0.63, indicating its price volatility relative to the broader market. Over the past 1 year, Pfizer Ltd. has delivered an absolute return of -32.30%.
What is the RSI of Pfizer Ltd.?
The 14-day Relative Strength Index (RSI) of Pfizer Ltd. is 28.12, placing it in the oversold zone. An RSI above 70 is considered overbought and below 30 is considered oversold.
Net Revenue FY
Profit After Tax FY
ROE FY
EBITDA FY
Mar 2020
Jun 2020
Sep 2020
Dec 2020
Mar 2021
Jun 2021
Sep 2021
Dec 2021
Mar 2022
Jun 2022
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Total Promoter
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
Indian Promoter
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Foreign Promoter
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
63.92
Institutions
16.35
16.92
16.89
16.18
16.52
16.90
17.22
17.16
17.26
17.38
17.43
17.70
17.69
17.70
17.82
18.18
18.65
19.06
19.57
19.54
19.28
19.62
19.70
19.76
19.70
19.45
19.15
Mutual Funds / UTI
9.34
9.70
10.48
9.07
8.42
8.70
8.48
8.29
7.94
7.17
6.51
5.97
5.96
6.17
7.39
7.61
7.72
8.32
10.43
11.30
11.59
11.70
11.74
11.71
11.52
12.68
12.83
FI/Bank/Insurance
3.03
3.13
2.56
3.84
4.67
4.69
0.51
0.55
0.63
0.75
8.34
8.93
8.90
8.69
7.58
7.54
7.45
7.41
5.53
5.41
5.45
5.47
5.37
5.32
5.33
5.10
4.67
Govt
-
0.00
0.00
0.00
0.00
-
0.00
0.00
0.00
0.00
0.00
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
FII
3.69
2.51
1.93
1.87
1.89
1.95
2.07
2.13
2.20
2.55
2.55
2.77
2.80
2.81
2.82
3.03
3.32
3.22
3.54
2.74
2.18
2.40
2.60
2.71
2.81
1.65
1.63
Other Institutions
0.27
1.58
1.92
1.40
1.55
1.57
6.16
6.18
6.49
13.79
0.03
0.03
0.03
0.03
0.03
0.00
0.15
0.10
0.07
0.09
0.06
0.06
0.00
0.02
0.04
0.02
0.02
Non-Institution
19.73
19.16
19.18
19.89
19.55
19.17
18.86
18.92
18.82
18.70
18.65
18.38
18.38
18.38
18.25
17.90
17.42
17.02
16.50
16.54
16.80
16.45
16.37
16.32
16.37
16.63
16.93
Bodies Corporate
2.95
3.28
3.12
2.86
2.78
2.91
3.09
3.02
3.00
2.99
2.97
2.92
2.94
2.94
2.83
2.81
2.77
2.72
2.65
2.65
2.67
2.66
2.51
2.58
2.71
2.78
2.89
Others (incl. Retail)
No. of shareholders
16.78
81,902
15.88
1,04,749
16.06
1,07,824
17.03
1,49,624
16.77
1,45,053
16.26
1,30,398
15.77
1,20,262
15.90
1,25,895
15.82
1,24,397
15.71
1,22,560
15.68
1,21,167
15.46
1,17,124
15.44
1,16,379
15.44
1,15,176
15.42
1,16,140
15.09
1,11,676
14.65
1,08,447
14.30
1,05,345
13.85
98,100
13.89
1,04,286
14.13
1,07,534
13.79
1,02,478
13.86
1,02,700
13.74
1,00,177
13.66
98,785
13.85
1,01,711
14.04
1,03,701
Corporate Actions
History of Pfizer Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.
Dividend₹ 75/share
Record date: 17th Jul 2026Ex-date: 17th Jul 2026
Announced on: 12th May 2026
Dividend₹ 35/share
Record date: 9th Jul 2025Ex-date: 9th Jul 2025
Announced on: 20th May 2025
Dividend₹ 130/share
Record date: 9th Jul 2025Ex-date: 9th Jul 2025
Announced on: 20th May 2025
Dividend₹ 35/share
Record date: 21st Aug 2024Ex-date: 21st Aug 2024
Announced on: 17th May 2024
Dividend₹ 35/share
Record date: 11th Aug 2023Ex-date: 11th Aug 2023
Announced on: 15th May 2023
Holdings and Presence
Indices and prominent investors with a stake in this stock.
Overview of Pfizer Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.
Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approved for administering to individuals of all ages against pneumococcal disease, an infection caused by streptococcus pneumoniae bacteria. Internal Medicine portfolio includes approximately 17 specialties and seven therapy areas, including respiratory, multivitamin and multimineral, gastrointestinal, pain, neuroscience, cardiovascular and women’s healthcare. Pfizer Hospital Business Unit focuses on providing advanced anti-infectives to institutions such as hospitals and nursing homes. Inflammation and Immunology focuses on discovering and developing novel therapeutics for chronic autoimmune diseases. Its brands include Prevenar13, CorexDX, Dolonex, Enbrel, Becosules and Folvite, among others.
Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approve...
The Capital, 1802 / 1901, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra East, MUMBAI, 400051, India
Stock Analysis
Fundamental analysis overview of Pfizer Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.
Views
Red Flags
Positive
Stock is reasonably valued and PE TTM is at a discount to industry median
PE TTM of 22.47 indicates that the stock is reasonably valued on a standalone basis. Discount to industry median P/E is decent at -26.26%
What is P/E Ratio?
Median: 30.47
Value 22.47
-0.82614.73
Consistently pays dividend
The company has not missed dividend payments once in the last 10 financial years
What is Dividend streak?
Company is net cash
The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet
What is Net Debt ?
Negative
Weak price momentum
Price Momentum score of 29.5 indicates that the stock has weak price momentum. Research has shown that stocks with lower momentum continue to underperform in the near term
What is Price Momentum score?
29.5 / 100
Analysts have been downgrading forward EPS estimates
Analyst EPS estimate (consensus) for forward EPS has decreased by -0.82% in the last 3 months, indicating weak earnings momentum
What is Earnings upgrade (3M)?
Neutral
Company's earnings are of moderate quality
Earnings quality score of 68.5 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion
What is Earnings quality score?
68.5 / 100
Moderate dividend yield
The company has a moderate dividend yield of 2.08%
What is Dividend yield?
No red flags found!
No significant red flags found in the stock.
3,610.35-78.5 (-2.13%)
-31.90% in past 1 year
Name
Date
Type
Price
Qty.
Value
Quant Mutual Fund
20 Aug 2026
buy
₹ 4,899.97
2.68 lac
-
Goldman Sachs Funds - Goldman Sachs India Equity Portfolio